Prothena Corporation plc (NASDAQ:PRTA) Given Average Recommendation of “Hold” by Analysts

Prothena Corporation plc (NASDAQ:PRTA) has earned a consensus rating of “Hold” from the eleven brokerages that are currently covering the firm, MarketBeat reports. Two equities research analysts have rated the stock with a sell rating, four have given a hold rating, four have issued a buy rating and one has issued a strong buy rating on the company. The average 1-year price objective among brokers that have issued a report on the stock in the last year is $22.00.

A number of equities research analysts have issued reports on the stock. Wall Street Zen upgraded shares of Prothena from a “sell” rating to a “hold” rating in a research note on Saturday, November 8th. Citizens Jmp set a $19.00 price target on shares of Prothena in a research report on Monday, December 1st. Royal Bank Of Canada boosted their price objective on shares of Prothena from $11.00 to $12.00 and gave the company a “sector perform” rating in a research report on Friday, February 20th. Weiss Ratings restated a “sell (e+)” rating on shares of Prothena in a research note on Monday, December 29th. Finally, HC Wainwright lifted their price target on Prothena from $20.00 to $30.00 and gave the company a “buy” rating in a research note on Friday, November 7th.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. Prospera Financial Services Inc acquired a new stake in shares of Prothena in the 2nd quarter valued at approximately $61,000. Tower Research Capital LLC TRC boosted its position in Prothena by 571.0% in the second quarter. Tower Research Capital LLC TRC now owns 12,709 shares of the biotechnology company’s stock valued at $77,000 after buying an additional 10,815 shares in the last quarter. Corton Capital Inc. acquired a new stake in Prothena in the second quarter valued at approximately $85,000. CWM LLC grew its stake in shares of Prothena by 650.1% during the third quarter. CWM LLC now owns 10,246 shares of the biotechnology company’s stock worth $100,000 after buying an additional 8,880 shares during the last quarter. Finally, ProShare Advisors LLC acquired a new position in shares of Prothena during the fourth quarter worth $100,000. Institutional investors and hedge funds own 97.08% of the company’s stock.

Prothena Price Performance

Prothena stock opened at $8.67 on Monday. The firm has a market cap of $466.71 million, a PE ratio of -1.91, a price-to-earnings-growth ratio of 1.06 and a beta of -0.24. The stock’s fifty day moving average price is $9.19 and its two-hundred day moving average price is $9.46. Prothena has a one year low of $4.32 and a one year high of $16.16.

Prothena (NASDAQ:PRTA) last released its earnings results on Thursday, February 19th. The biotechnology company reported ($0.44) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.45) by $0.01. Prothena had a negative return on equity of 62.53% and a negative net margin of 2,520.57%.The company had revenue of $0.02 million for the quarter, compared to analyst estimates of $0.67 million. Sell-side analysts expect that Prothena will post -4.04 earnings per share for the current fiscal year.

About Prothena

Prothena Corporation plc is a clinical-stage biotechnology company dedicated to the discovery and development of novel therapies for neurodegenerative and rare diseases driven by misfolded proteins. The company’s research focuses on immunotherapies and small molecules designed to target and clear disease-causing protein aggregates. Prothena leverages proprietary protein engineering and antibody discovery platforms to advance candidates through preclinical and clinical stages.

The company’s most advanced program is an antibody targeting aggregated alpha-synuclein for the potential treatment of Parkinson’s disease, currently in mid-stage clinical trials.